(Q36057459)

English

Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

0 references

1 reference

based on heuristic

inferred from title

Nai-Kong V Cheung

1

object named as

Nai-Kong V Cheung

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

5

object named as

Irene Y Cheung

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

author name string

Hongfen Guo

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Jian Hu

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Dimiter V Tassev

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

publication date

1 July 2012

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

477-486

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Emerging importance of ALK in neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

2 October 2017

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

2 October 2017

Anti-GD2 antibody therapy for GD2-expressing tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

2 October 2017

Reducing epitope spread during affinity maturation of an anti-ganglioside GD2 antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

2 October 2017

Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

2 October 2017

Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

2 October 2017

Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

2 October 2017

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

2 October 2017

Antibody-based therapy for solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

2 October 2017

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

2 October 2017

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

2 October 2017

Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

2 October 2017

Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

2 October 2017

Alterations in neuroblastoma ganglioside synthesis by induction of GD1b synthase by retinoic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

2 October 2017

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

2 October 2017

CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

2 October 2017

Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

2 October 2017

Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

2 October 2017

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

11 July 2018

Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

11 July 2018

Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

11 July 2018

Monoclonal antibody 3F8 recognises the neural cell adhesion molecule (NCAM) in addition to the ganglioside GD2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

11 July 2018

Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

11 July 2018

Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma.

1 reference

https://api.crossref.org/works/10.4161/ONCI.19864

21 January 2018

The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.

1 reference

https://api.crossref.org/works/10.4161/ONCI.19864

21 January 2018

Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and az

1 reference

https://api.crossref.org/works/10.4161/ONCI.19864

21 January 2018

High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy

1 reference

https://api.crossref.org/works/10.4161/ONCI.19864

21 January 2018

Quality of surveillance for stage I testis cancer in the community

1 reference

https://api.crossref.org/works/10.4161/ONCI.19864

21 January 2018

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

1 reference

https://api.crossref.org/works/10.4161/ONCI.19864

21 January 2018

Localization of major gangliosides in the PNS: implications for immune neuropathies

1 reference

https://api.crossref.org/works/10.4161/ONCI.19864

21 January 2018

Direct immobilization of gangliosides onto gold-carboxymethyldextran sensor surfaces by hydrophobic interaction: applications to antibody characterization

1 reference

https://api.crossref.org/works/10.4161/ONCI.19864

21 January 2018

Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

23 September 2018

Biological stratification of human neuroblastoma by complex "B" pathway ganglioside expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

23 September 2018

Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

23 September 2018

Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

23 September 2018

A mechanism for neutrophil-mediated lysis of human neuroblastoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

23 September 2018

Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3382886

23 September 2018

FCGR2APolymorphism Is Correlated With Clinical Outcome After Immunotherapy of Neuroblastoma With Anti-GD2 Antibody and Granulocyte Macrophage Colony-Stimulating Factor

1 reference

https://api.crossref.org/works/10.4161/ONCI.19864

21 January 2018

Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.4161/ONCI.19864

21 January 2018

Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/22754766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-level expression of chimeric antibodies using adapted cDNA variable region cassettes

1 reference

https://pubmed.ncbi.nlm.nih.gov/22754766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22754766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's

1 reference

https://pubmed.ncbi.nlm.nih.gov/22754766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/22754766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review

1 reference

https://pubmed.ncbi.nlm.nih.gov/22754766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22754766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Approved monoclonal antibodies for cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22754766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4161/ONCI.19864

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36057459&oldid=2186319186"